Silence Therapeutics plc financial data

Symbol
SLN on Nasdaq, SLNCF on OTC
Location
London
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 937% %
Debt-to-equity 69% %
Return On Equity -62% %
Return On Assets -37% %
Operating Margin -321% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 141,701,848 shares
Common Stock, Shares, Outstanding 141,701,848 shares
Entity Public Float $737,900,000 USD
Common Stock, Value, Issued $10,290,000 USD
Weighted Average Number of Shares Outstanding, Basic 141,701,848 shares 0.36%
Weighted Average Number of Shares Outstanding, Diluted 141,701,848 shares 0.36%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $25,830,000 USD -89%
Research and Development Expense $81,081,000 USD 1.9%
General and Administrative Expense $24,153,000 USD -25%
Operating Income (Loss) $82,969,000 USD 13%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $64,205,000 USD 41%
Income Tax Expense (Benefit) $335,000 USD -98%
Net Income (Loss) Attributable to Parent $64,540,000 USD 41%
Earnings Per Share, Basic 0 USD/shares 40%
Earnings Per Share, Diluted 0 USD/shares 40%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $82,031,000 USD
Cash, Cash Equivalents, and Short-term Investments $102,200,000 USD
Accounts Receivable, after Allowance for Credit Loss, Current $28,000 USD
Other Assets, Current $9,260,000 USD
Assets, Current $133,632,000 USD
Property, Plant and Equipment, Net $1,655,000 USD
Operating Lease, Right-of-Use Asset $192,000 USD
Goodwill $10,612,000 USD 13%
Other Assets, Noncurrent $399,000 USD
Assets $146,790,000 USD
Contract with Customer, Liability, Current $301,000 USD
Liabilities, Current $17,379,000 USD
Contract with Customer, Liability, Noncurrent $55,251,000 USD
Operating Lease, Liability, Noncurrent $97,000 USD
Liabilities $72,727,000 USD
Accumulated Other Comprehensive Income (Loss), Net of Tax $3,073,000 USD
Retained Earnings (Accumulated Deficit) $550,802,000 USD
Stockholders' Equity Attributable to Parent $74,063,000 USD -42%
Liabilities and Equity $146,790,000 USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $12,309,000 USD -35%
Net Cash Provided by (Used in) Financing Activities $133,020,000 USD
Net Cash Provided by (Used in) Investing Activities $44,381,000 USD 11%
Common Stock, Shares, Issued 141,701,848 shares
Common Stock, Par or Stated Value Per Share 0.05 GBP/shares
Deferred Tax Assets, Valuation Allowance $61,446,000 USD -3.6%
Deferred Tax Assets, Gross $61,446,000 USD -3.6%
Operating Lease, Liability $117,000 USD
Depreciation $73,000 USD -17%
Payments to Acquire Property, Plant, and Equipment $4,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $64,691,000 USD 19%
Lessee, Operating Lease, Liability, to be Paid $117,000 USD
Property, Plant and Equipment, Gross $6,343,000 USD -1.4%
Operating Lease, Liability, Current $85,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $117,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) $0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD
Deferred Tax Assets, Net of Valuation Allowance $0 USD